Clinical trials: HIV 1 Infection
HIV Infections
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
- Trial name
- NCT00002236
- Testing
- Indinavir sulfate, Delavirdine mesylate, Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pharmacia and Upjohn
HIV-1 Infection
Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
Background: Despite the introduction of highly effective antiretroviral therapy (ART) regimes, which control the HIV infection and results in increases in CD4 cell counts and an undetectable viral load, many patients suffer from…
- Trial name
- NCT01627678
- Testing
- Vacc-C5/GM-CSF, Vacc-C5/Alhydrogel
- Where
- Norway
- Volunteers
- 36 people
- Sponsor
- Bionor Immuno AS
HIV Infections
Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents
First-line antiretroviral regimens are highly efficacious and generally well tolerated. However, as these regimens need to be taken life-long, there is growing concern about long-term toxicities associated with these regimens.
- Trial name
- NCT03682848
- Testing
- DTG + 3TC FDC
- Where
- 8 sites in Kenya, South Africa and 1 more
- Volunteers
- 32 people
- Sponsor
- ViiV Healthcare
HIV Infections
Feasibility Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine)
The purpose of this trial was to evaluate the safety and feasibility of using a vaginal ring to deliver the candidate microbicide TMC120 (dapivirine).
- Trial name
- NCT00700284
- Testing
- TMC120 (dapivirine) vaginal ring
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infections
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine).
- Trial name
- NCT00002240
- Testing
- Atazanavir, Nelfinavir mesylate, Stavudine
- Where
- 17 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
HIV-1 Infection
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
The primary objective of this study is to evaluate the noninferiority of switching to emtricitabine/rilpivirine /tenofovir alafenamide (FTC/RPV/TAF) fixed-dose combination (FDC) as compared to continuing FTC/RPV/tenofovir…
- Trial name
- NCT02345252
- Testing
- FTC/RPV/TAF, FTC/RPV/TDF
- Where
- 117 sites in United States, Belgium and 10 more
- Volunteers
- 632 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
This open-label study will evaluate the safety, pharmacokinetics and antiviral activity of a modified Invirase (saquinavir)/ritonavir regimen in treatment-naïve HIV-1 infected patients.
- Trial name
- NCT01638650
- Testing
- Nucleoside Reverse Transcriptase Inhibitor (NRTIs), ritonavir, saquinavir [Invirase]
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
AIDS
Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons
This study is designed to determine whether administration of the GSK Biologicals HIV vaccine 732462 can lead to a reduction in viral load, and impact on the course of human immunodeficiency virus type 1 (HIV-1) infection.
- Trial name
- NCT01218113
- Testing
- GSK Biologicals HIV Vaccine 732462
- Where
- 42 sites in United States, France and 2 more
- Volunteers
- 191 people
- Sponsor
- GlaxoSmithKline
HIV-1-infection
Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects
To assess the safety and tolerability of Elsulfavirine following administration of single oral ascending doses in HIV-negative, healthy subjects.
- Trial name
- NCT05165550
- Testing
- Elsulfavirine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Viriom
HIV Infections
A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients
Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings in patients infected with…
- Trial name
- NCT00002050
- Testing
- Thymopentin
- Where
- United States
- Sponsor
- Immunobiology Research Institute